Pharma News, 2022

Denmark-based Bavarian Nordic A/S announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for MVA-BN RSV, a vaccine candidate for active immunizati...

Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-approve...

Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment for secondary...

Researchers have identified a powerful combination of antivirals to treat COVID-19. Combining the drug brequniar with remdesivir or molnupiravir -- both approved by the U.S. Food and Drug Administ...

Qurient Co. Ltd., a clinical stage biotech company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for Q901, a small mol...

Glenmark Pharmaceuticals reported that its anti-microbial nitric oxide nasal spray (NONS) had positive results in a phase 3 trial in 306 nonhospitalized adult Indian patients with COVID-19. ...

Indian generic drugmaker Lupin got FDA approval for its nebulization-only medicine for long-term maintenance of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), in...

Drugs produced in China account for a significant share of the US market. 

Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that VCN Biosciences, S.L.'s (VCN) V...

The deal includes $150 million of cash payments over 15 years and $75 million of the overdose-fighting medication Narcan (Naloxone).

A team of scientists led by Cold Spring Harbor Laboratory (CSHL) have discovered that disulfiram, an FDA-approved drug, prevents the immune system from producing toxic webs known as neutrophil ext...

Phase 2 testing of a Lyme disease vaccine candidate, VLA15, produced strong immune responses, according to the newest data from Valneva SE and Pfizer inc, prompting preparations for a Phase 3 study...